FindTrial
Sign In

Efficacy and safety of subsequent treatment with 90Y-Zevalin in patients with stage II to IV follicular non-Hodgkin?s lymphoma in partial or complete remission after oral fludarabine and mitoxantrone front-line treatment. A phase II prospective, multicenter, open-label study.

Efficacy and safety of subsequent treatment with 90Y-Zevalin in patients with stage II to IV follicular non-Hodgkin?s lymphoma in partial or complete remission after oral fludarabine and mitoxantrone front-line treatment. A phase II prospective, multicenter, open-label study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-002211-92-IT
Enrollment
Unknown
Registered
2004-09-16
Start date
2004-07-06
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Remission induced (CR or PR) stage II to IV follicular non-Hodgkin?s lymphoma patients. MedDRA version: 6.1 Level: PT Classification code 10003904

Interventions

Trade Name: Zevalin Product Name: Zevalin Pharmaceutical Form: Solution for injection INN or Proposed INN: ibritumomab tiuxetan Concentration unit: mg milligram(s) Concentration type: equal Concentra

Sponsors

AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026